Literature DB >> 2538818

An in vitro system for infection with hepatitis B virus that uses primary human fetal hepatocytes.

T Ochiya1, T Tsurimoto, K Ueda, K Okubo, M Shiozawa, K Matsubara.   

Abstract

An in vitro culture of human fetal hepatocytes has been employed for infection by hepatitis B virus (HBV) virions that are produced by an established human hepatoma cell line, HB 611. HBV surface antigen and e antigen were released into the medium 3-4 days after infection, and production continued thereafter. RNA synthesis with similar kinetics was observed. Viral DNA replication started 2 days after infection, and replicative HBV DNA that included relaxed circles, single-stranded minus strands, and closed circles accumulated during 16 days of incubation. Immunofluorescent study using fluorescein isothiocyanate-labeled rabbit antisera directed against HBV core antigen revealed that this antigen is present in the nuclei in 12% of the infected cells. Particles containing HBV DNA were detected in the culture medium and were infectious. Thus, this in vitro infection system closely mimics infection in vivo and it allows detailed studies on early events associated with human HBV entry into cells and subsequent replication and integration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2538818      PMCID: PMC286807          DOI: 10.1073/pnas.86.6.1875

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Enzyme-labeled antibodies: preparation and application for the localization of antigens.

Authors:  P K Nakane; G B Pierce
Journal:  J Histochem Cytochem       Date:  1966-12       Impact factor: 2.479

2.  Demonstration of subpopulations of Dane particles.

Authors:  P M Kaplan; E C Ford; R H Purcell; J L Gerin
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

3.  Evidence for the multiplication of hepatitis B virus in "oval cell" culture originated from human embryonic liver.

Authors:  M Watanabe; T Umenai; H Ohori; N Ishida
Journal:  Br J Exp Pathol       Date:  1976-04

4.  Changes induced by hepatitis serum in cultured liver cells.

Authors:  W D Brighton; P E Taylor; A J Zuckerman
Journal:  Nat New Biol       Date:  1971-07-14

5.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

6.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

7.  Infection of human cells in culture with hepatitis B virus.

Authors:  S Z Hirschman; E Garfinkel
Journal:  Trans Assoc Am Physicians       Date:  1980

8.  Cloned HBV DNA causes hepatitis in chimpanzees.

Authors:  H Will; R Cattaneo; H G Koch; G Darai; H Schaller; H Schellekens; P M van Eerd; F Deinhardt
Journal:  Nature       Date:  1982-10-21       Impact factor: 49.962

9.  Studies on primary cultures of differentiated fetal liver cells.

Authors:  H L Leffert; D Paul
Journal:  J Cell Biol       Date:  1972-03       Impact factor: 10.539

10.  Australia antigen as a marker of propagation of the serum hepatitis virus in liver cultures.

Authors:  A J Zuckerman; P M Baines; J D Almeida
Journal:  Nature       Date:  1972-03-10       Impact factor: 49.962

View more
  27 in total

1.  Humanized murine model for HBV and HCV using human induced pluripotent stem cells.

Authors:  Xiao-Ling Zhou; Gareth J Sullivan; Pingnan Sun; In-Hyun Park
Journal:  Arch Pharm Res       Date:  2012-02-28       Impact factor: 4.946

Review 2.  Hepatitis B virus. New and evolving issues.

Authors:  B Yoffe; C A Noonan
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

3.  Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle.

Authors:  Hironori Nishitsuji; Hiromi Yamamoto; Ritsuko Shiina; Keisuke Harada; Saneyuki Ujino; Kunitada Shimotohno
Journal:  J Vis Exp       Date:  2017-02-01       Impact factor: 1.355

4.  Analysis of Host Responses to Hepatitis B and Delta Viral Infections in a Micro-scalable Hepatic Co-culture System.

Authors:  Benjamin Y Winer; Jenna M Gaska; Gabriel Lipkowitz; Yaron Bram; Amit Parekh; Lance Parsons; Robert Leach; Rohit Jindal; Cheul H Cho; Anil Shrirao; Eric Novik; Robert E Schwartz; Alexander Ploss
Journal:  Hepatology       Date:  2019-08-09       Impact factor: 17.425

5.  Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line.

Authors:  Darong Yang; Chaohui Zuo; Xiaohong Wang; Xianghe Meng; Binbin Xue; Nianli Liu; Rong Yu; Yuwen Qin; Yimin Gao; Qiuping Wang; Jun Hu; Ling Wang; Zebin Zhou; Bing Liu; Deming Tan; Yang Guan; Haizhen Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-10       Impact factor: 11.205

6.  Hepatitis B virus infection and replication in primarily cultured human fetal hepatocytes.

Authors:  Min Lin; Qun Chen; Li-Ye Yang; Wen-Yu Li; Xi-Biao Cao; Jiao-Ren Wu; You-Peng Peng; Mo-Rui Chen
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

7.  Acute hepatitis in rats expressing human hepatitis B virus transgenes.

Authors:  H Takahashi; J Fujimoto; S Hanada; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Efficient duck hepatitis B virus production by an avian liver tumor cell line.

Authors:  L D Condreay; C E Aldrich; L Coates; W S Mason; T T Wu
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

9.  Protease-induced infectivity of hepatitis B virus for a human hepatoblastoma cell line.

Authors:  X Lu; T M Block; W H Gerlich
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes.

Authors:  L D Condreay; J P Condreay; R W Jansen; M T Paff; D R Averett
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.